Efficacy and safety of diacerein in osteoarthritis of the knee

Pelletier, Jean-Pierre, Yaron, Michael, Haraoui, Boulos, Cohen, Patrick, Nahir, Menahem A., Choquette, Denis, Wigler, Irina, Rosner, Itzhak A., Beaulieu, André D., Bellamy, Nicholas and Diacerein Study Group (2000) Efficacy and safety of diacerein in osteoarthritis of the knee. Arthritis & Rheumatism, 43 10: 2339-2348. doi:10.1002/1529-0131(200010)43:10%3C2339::AID-ANR23%3E3.0.CO;2-P


Author Pelletier, Jean-Pierre
Yaron, Michael
Haraoui, Boulos
Cohen, Patrick
Nahir, Menahem A.
Choquette, Denis
Wigler, Irina
Rosner, Itzhak A.
Beaulieu, André D.
Bellamy, Nicholas
Diacerein Study Group
Title Efficacy and safety of diacerein in osteoarthritis of the knee
Journal name Arthritis & Rheumatism   Check publisher's open access policy
ISSN 1529-0131
0004-3591
Publication date 2000-10
Sub-type Article (original research)
DOI 10.1002/1529-0131(200010)43:10%3C2339::AID-ANR23%3E3.0.CO;2-P
Volume 43
Issue 10
Start page 2339
End page 2348
Total pages 10
Place of publication Hoboken, NJ, U.S.A.
Publisher Lippincott William & Wilkins
Collection year 2000
Language eng
Subject C1
321202 Epidemiology
730114 Skeletal system and disorders (incl. arthritis)
Formatted abstract
Objective
To evaluate the efficacy and safety of diacerein, a drug with interleukin-1β–inhibitory activity in vitro, in patients with knee osteoarthritis (OA).

Methods

A total of 484 patients fulfilling the American College of Rheumatology criteria for knee OA were enrolled in this 16-week, randomized, double-blind, placebo-controlled, parallel study group with 3 diacerein dosages of 50 mg/day, 100 mg/day, and 150 mg/day (administered twice daily).

Results

In the intent-to-treat population, 100 mg/day diacerein (50 mg twice daily) was significantly superior (P < 0.05) to placebo using the primary criterion (visual analog scale [VAS] assessment of pain on movement). Significant improvement (P < 0.05) was also observed for the secondary criteria, which included the Western Ontario and McMaster Universities OA Index (WOMAC), the WOMAC subscores, and the VAS assessment of handicap. In patients treated with diacerein dosages of 50 mg/day and 150 mg/day, favorable but not significant results were observed for the primary criterion. The best daily dosage of diacerein, calculated from the effect on the VAS assessment of pain on movement, was 90.1 mg. In the per-protocol population, the analysis of the primary criterion showed significant dose-dependent differences (P < 0.05) between each of the 3 diacerein dosages and the placebo. No differences were observed among the 3 diacerein groups. A significantly higher incidence (P < 0.05) of adverse events (AEs), as well as a higher rate of dropoout due to AEs, was observed in patients treated with 150 mg/day diacerein versus those treated with placebo, 50 mg/day diacerein, or 100 mg/day diacerein. Mild-to-moderate transient changes in bowel habits were the most frequent AEs, increasing with the dosage.

Conclusion
Diacerein, a drug for the treatment of OA, was shown to be an effective treatment for symptoms in patients with knee OA. Taking into account both efficacy and safety, the optimal daily dosage of diacerein for patients with knee OA is 100 mg/day (50 mg twice daily).
© 2000, American College of Rheumatology
Q-Index Code C1

Document type: Journal Article
Sub-type: Article (original research)
Collection: School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: Google Scholar Search Google Scholar
Created: Tue, 10 Jun 2008, 13:05:21 EST